2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Michael J. Wagner, MD, discusses the importance of cooperative research groups in angiocarcinoma.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Michael J. Wagner, MD, assistant professor, University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, discusses the importance of cooperative research groups in angiocarcinoma.
Angiosarcoma is a rare subset of an already rare disease, soft tissue sarcomas. Due to the lack of patients, it can be difficult for single institutions to recruit enough participants to conduct clinical trials.
Clinical trials requires collaboration, according to Wagner, who calls cooperative groups like EGOC, the Alliance, and SWOG "critical" for conducting research. Findings from the Angiosarcoma Project discovered the connection between exposure to ultraviolet light and angiosarcoma.
Related Content: